Carlsmed

CARL

Market cap $335M

CARLSBAD, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced that Mike Cordonnier, Chairman and CEO of Carlsmed will be presenting at the J.P. Morgan 2026 Healthcare conference on Wednesday, January 14th at 4:30-5:10 pm PT in San Francisco, CA. During the conference, Carlsmed Management will be hosting 1x1 investor meetings.

Carlsmed launches personalized aprevo cervical platform with early cases and new reimbursement support driving momentum in spine surgery.

First 50+ cervical cases completed; observations on initial clinical experience to be presented by early adopters at the Carlsmed CSRS Lunch Workshop First 50+ cervical cases completed; observations on initial clinical experience to be presented by early adopters at the Carlsmed CSRS Lunch Workshop

CARLSBAD, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced that Mike Cordonnier, Chairman and CEO of Carlsmed, will be presenting at the 37th Annual Piper Sandler Healthcare conference on Wednesday, December 3rd at 9:00-9:25 am ET in New York, NY. During the conference, Carlsmed Management will be hosting 1x1 investor meetings.

Third quarter revenue of $13.1 million, representing 98% growth YoY  Raising full year 2025 revenue guidance to $49 million - $50 million CARLSBAD, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today reported financial results for the third quarter ended September 30, 2025.

CARLSBAD, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced it will report its third quarter 2025 financial results after market close on Thursday, November 6, 2025. Management will also host a conference call and concurrent webcast starting at 1:30 PM Pacific Time.

CARLSBAD, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced the appointment of Jenifer Kamocsay as Chief Legal Officer and Secretary, effective immediately. Ms. Kamocsay will serve as legal counsel for the Company and oversee compliance and corporate governance.

CARLSBAD, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that effective after market close on September 22, 2025, it has been added to the Russell 2000® Index. This was part of the planned additions of select companies to this Index that had their IPO in the third quarter of 2025.

Q2'25 revenue of $12.1 million, 99% YOY growth Full year revenue guidance of $45.5M - $47.5M CARLSBAD, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today reported financial results for the second quarter ended June 30, 2025.

Q2'25 revenue of $12.1 million, 99% YOY growth Full year revenue guidance of $45.5M - $47.5M CARLSBAD, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today reported financial results for the second quarter ended June 30, 2025.